CA2236579C - Methods and compositions for the delivery of monomeric proteins - Google Patents
Methods and compositions for the delivery of monomeric proteins Download PDFInfo
- Publication number
- CA2236579C CA2236579C CA002236579A CA2236579A CA2236579C CA 2236579 C CA2236579 C CA 2236579C CA 002236579 A CA002236579 A CA 002236579A CA 2236579 A CA2236579 A CA 2236579A CA 2236579 C CA2236579 C CA 2236579C
- Authority
- CA
- Canada
- Prior art keywords
- insulin
- multimeric
- protein
- monomeric
- chelating agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Abstract
Methods and devices for dissociating multimeric proteins and their delivery to patients, along with resultant compositions, are provided. A monomeric protein delivery device is also provided, comprising a supply of a multimeric protein (4) complex, comprising multimeric protein and an aggregating agent; a flow path having a subcutaneous exit (8) , fluidly coupling the multimeric protein supply to the exit; a porous surface assembly situated along the flow path comprising a porous surface (10); and an aggregating agent binding partner carried by the surface (12); whereby the aggreagating agent of the multimeric protei n complex passing along the surface is bound to the binding partner on the surface to create a monomeric protein flow through the subcutaneous exit.
Description
METHODS AND COMPOSITIONS FOR THE DELIVERY OF
MONOMERIC PROTEINS
This application is a continuation-in-part of and claims the benefit of U.S.
provisional application no. 60/006,611.
BACKGROUND OF THE INVENTION
Insulin exists in solution as a monomer in equilibrium with dimers and hexamers. When these fotms are administered to a patient, the multimeric fotms must dissociate in the body to a monomeric form, which is then absorbed by capillaries in the body. This is disadvantageous in situations where a patient must "plan ahead"
to the time insulin is actually required by the body. For example, a patient must give himself or herself a "meal bolus" of regular insulin 25 to 40 minutes before each meal.
Pumps (e.g., MinimedT ^) are available for delivery of insulin to a patient, whereby microinfusions of insulin can be delivered in a programmable fashion to a patient. Although these microinfusions reduce the need for administering a meal bolus in advance of a meal, there is still a delay in absorption of the hexameric insulin delivered.
Thus, there exists a need for a method for delivering monomeric insulin to a patient. The instant invention addresses this problem and more.
SUMMARY OF THE INVENTION
One aspect of the invention is a method of delivering a monomeric protein preparation to a patient comprising (a) providing a surface coated with a binding partner for an aggregating agent, the aggregating agent being present in a preparation of a multimeric protein; and (b) administering a preparation of the multimeric protein to the patient via the surface of step (a), whereby the aggregating agent in the multimeric preparation binds to the binding partner on the surface and the multimeric protein is dissociated into monomers.
MONOMERIC PROTEINS
This application is a continuation-in-part of and claims the benefit of U.S.
provisional application no. 60/006,611.
BACKGROUND OF THE INVENTION
Insulin exists in solution as a monomer in equilibrium with dimers and hexamers. When these fotms are administered to a patient, the multimeric fotms must dissociate in the body to a monomeric form, which is then absorbed by capillaries in the body. This is disadvantageous in situations where a patient must "plan ahead"
to the time insulin is actually required by the body. For example, a patient must give himself or herself a "meal bolus" of regular insulin 25 to 40 minutes before each meal.
Pumps (e.g., MinimedT ^) are available for delivery of insulin to a patient, whereby microinfusions of insulin can be delivered in a programmable fashion to a patient. Although these microinfusions reduce the need for administering a meal bolus in advance of a meal, there is still a delay in absorption of the hexameric insulin delivered.
Thus, there exists a need for a method for delivering monomeric insulin to a patient. The instant invention addresses this problem and more.
SUMMARY OF THE INVENTION
One aspect of the invention is a method of delivering a monomeric protein preparation to a patient comprising (a) providing a surface coated with a binding partner for an aggregating agent, the aggregating agent being present in a preparation of a multimeric protein; and (b) administering a preparation of the multimeric protein to the patient via the surface of step (a), whereby the aggregating agent in the multimeric preparation binds to the binding partner on the surface and the multimeric protein is dissociated into monomers.
A further aspect of the invention is a method for dissociating a multimeric insulin complex, method comprising:
(a) binding a zinc chelating agent to a surface;
(b) contacting the surface with the multimeric insulin complex, whereby zinc associated with the multimeric insulin complex binds to the zinc chelating agent and the multimeric insulin is dissociated into monomers; and (c) recovering monomeric insulin generated by step (b).
A further aspect of the invention is a method of delivering monomeric insulin to a patient comprising:
(a) providing a zinc chelating agent bound to a surface;
(b) contacting the surface with multimeric insulin, whereby zinc binds to the chelating agent and the multimeric insulin is dissociated into monomers; and (c) delivering the monomeric insulin to a patient.
A further aspect of the invention is a monomeric protein delivery device comprising:
a supply of a multimeric protein complex, comprising multimeric protein and an aggregating agent;
a flow path having a subcutaneous exit, fluidly coupling the multimeric protein supply to the exit; and a carrier surface assembly situated along the flow path comprising a carrier surface; and an aggregating agent binding partner carried by the carrier surface;
whereby the aggregating agent of the multimeric protein complex contacting the carrier surface is bound to the binding partner on the surface to create a monomeric protein flow through the subcutaneous exit.
According to one embodiment, there is disclosed the use of a surface carrying a binding partner for an aggregating agent, to treat a patient with a monomer of a multimeric protein by dissociating the multimeric protein into the monomers.
According to a further embodiment, there is disclosed the use wherein the metal aggregating agent binds to the metal chelating agent binding partner on the surface.
2a According to a further embodiment, there is disclosed the use wherein the metal aggregating agent is in a preparation of a multimeric protein.
According to a further embodiment, there is disclosed the use wherein the monomeric protein is insulin.
According to a further embodiment, there is disclosed the use wherein the metal aggregating agent is zinc.
According to a further embodiment, there is disclosed the use wherein the binding partner is a chelating agent.
According to a further embodiment, there is disclosed the use wherein the chelating agent is an ion exchange medium.
According to a further embodiment, there is disclosed the use wherein the surface is a membrane.
According to a further embodiment, there is disclosed the use wherein the membrane comprises pores of about 4000 to about 20,000MW.
According to a further embodiment, there is disclosed the use wherein the multimeric protein is pumped through the surface.
According to a further embodiment, there is disclosed the use wherein the surface is adapted to be implantable.
According to a further embodiment, there is disclosed a method for dissociating a multimeric insulin, the method comprising: (a) binding a zinc chelating agent to a surface; (b) contacting the surface with the multimeric insulin, whereby the zinc binds to the chelating agent and the multimeric insulin is dissociated into monomers; and (c) recovering monomeric insulin generated by step (b).
According to a further embodiment, there is disclosed the use of a preparation made by the method above wherein the monomeric insulin is suitable for administration to a patient.
According to a further embodiment, there is disclosed the use further comprising pumping the monomeric insulin.
According to a further embodiment, there is disclosed the method wherein the surface is adapted to be implantable.
According to a further embodiment, there is disclosed the use of a zinc chelating agent bound to a surface to treat a patient with monomeric insulin binding a zinc 2b aggregating agent associated with a multimeric insulin complex with the zinc chelating agent carried on the surface and by dissociating multimeric insulin into the monomeric insulin. According to a further embodiment, there is disclosed the use comprising contacting the multimeric insulin with the surface on an insulin delivery device and dissociating the multimeric insulin into monomers.
According to a further embodiment, there is disclosed a monomeric protein delivery device comprising: a supply of a multimeric protein complex, comprising multimeric protein and metal aggregating agent; a flow path having a subcutaneous exit, fluidly coupling the multimeric protein supply to the exit; and a porous matrix situated along the flow path comprising: a surface; and a metal chelating agent for the metal aggregating agent; whereby the aggregating agent of the multimeric protein complex contacting the surface is bound to the metal chelating agent to create a monomeric protein flow through the subcutaneous exit.
According to a further embodiment, there is disclosed the device wherein the supply of multimeric protein complex comprises a supply of multimeric insulin.
According to a further embodiment, there is disclosed the device wherein the metal chelating agent is selected from the group consisting of an organic alcohol, a non-acetic acid amine, a phosphine and an organic sulfonate.
According to a further embodiment, there is disclosed the device wherein the metal chelating agent is Nafion .
According to a further embodiment, there is disclosed the device wherein the metal aggregating agent is zinc.
According to a further embodiment, there is disclosed the device wherein the flow path assembly comprises a catheter.
According to a further embodiment, there is disclosed the device wherein the flow path assembly comprises a pump for pumping the multimeric protein complex along the flow path.
According to a further embodiment, there is disclosed the device wherein the pump is adapted to be external to a patient.
According to a further embodiment, there is disclosed the device wherein the pump is adapted to be implantable in a patient to receive the monomeric protein.
2c According to a further embodiment, there is disclosed the device wherein the porous matrix has a porosity of about 4000-20,000 MW.
According to a further embodiment, there is disclosed a kit comprising: (a) the device according to any one of the other embodiments; and (b) instructions to use it to treat a patient.
According to a further embodiment, there is provided a surface carrying a metal chelating agent binding partner for a metal aggregating agent that is associated with a multimeric protein, to generate a monomer of a multimeric protein by binding the metal aggregating agent with the metal chelating agent binding partner carried on the surface and dissociating the multimeric protein into monomers.
According to a further embodiment, a zinc chelating agent bound to a surface for the preparation of monomeric insulin by binding a zinc aggregating agent associated with a multimeric insulin complex with the zinc chelating agent carried on the surface and dissociating multimeric insulin into the monomeric insulin.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a schematic drawing of a device for delivering monomeric protein.
Figs. 2-5 are simplified views of four embodiments of the device of Fig.1.
Fig. 6 is a schematic drawing of a device for delivering monomeric proteins comprising a catheter and a diffusion membrane mounted at one end.
(a) binding a zinc chelating agent to a surface;
(b) contacting the surface with the multimeric insulin complex, whereby zinc associated with the multimeric insulin complex binds to the zinc chelating agent and the multimeric insulin is dissociated into monomers; and (c) recovering monomeric insulin generated by step (b).
A further aspect of the invention is a method of delivering monomeric insulin to a patient comprising:
(a) providing a zinc chelating agent bound to a surface;
(b) contacting the surface with multimeric insulin, whereby zinc binds to the chelating agent and the multimeric insulin is dissociated into monomers; and (c) delivering the monomeric insulin to a patient.
A further aspect of the invention is a monomeric protein delivery device comprising:
a supply of a multimeric protein complex, comprising multimeric protein and an aggregating agent;
a flow path having a subcutaneous exit, fluidly coupling the multimeric protein supply to the exit; and a carrier surface assembly situated along the flow path comprising a carrier surface; and an aggregating agent binding partner carried by the carrier surface;
whereby the aggregating agent of the multimeric protein complex contacting the carrier surface is bound to the binding partner on the surface to create a monomeric protein flow through the subcutaneous exit.
According to one embodiment, there is disclosed the use of a surface carrying a binding partner for an aggregating agent, to treat a patient with a monomer of a multimeric protein by dissociating the multimeric protein into the monomers.
According to a further embodiment, there is disclosed the use wherein the metal aggregating agent binds to the metal chelating agent binding partner on the surface.
2a According to a further embodiment, there is disclosed the use wherein the metal aggregating agent is in a preparation of a multimeric protein.
According to a further embodiment, there is disclosed the use wherein the monomeric protein is insulin.
According to a further embodiment, there is disclosed the use wherein the metal aggregating agent is zinc.
According to a further embodiment, there is disclosed the use wherein the binding partner is a chelating agent.
According to a further embodiment, there is disclosed the use wherein the chelating agent is an ion exchange medium.
According to a further embodiment, there is disclosed the use wherein the surface is a membrane.
According to a further embodiment, there is disclosed the use wherein the membrane comprises pores of about 4000 to about 20,000MW.
According to a further embodiment, there is disclosed the use wherein the multimeric protein is pumped through the surface.
According to a further embodiment, there is disclosed the use wherein the surface is adapted to be implantable.
According to a further embodiment, there is disclosed a method for dissociating a multimeric insulin, the method comprising: (a) binding a zinc chelating agent to a surface; (b) contacting the surface with the multimeric insulin, whereby the zinc binds to the chelating agent and the multimeric insulin is dissociated into monomers; and (c) recovering monomeric insulin generated by step (b).
According to a further embodiment, there is disclosed the use of a preparation made by the method above wherein the monomeric insulin is suitable for administration to a patient.
According to a further embodiment, there is disclosed the use further comprising pumping the monomeric insulin.
According to a further embodiment, there is disclosed the method wherein the surface is adapted to be implantable.
According to a further embodiment, there is disclosed the use of a zinc chelating agent bound to a surface to treat a patient with monomeric insulin binding a zinc 2b aggregating agent associated with a multimeric insulin complex with the zinc chelating agent carried on the surface and by dissociating multimeric insulin into the monomeric insulin. According to a further embodiment, there is disclosed the use comprising contacting the multimeric insulin with the surface on an insulin delivery device and dissociating the multimeric insulin into monomers.
According to a further embodiment, there is disclosed a monomeric protein delivery device comprising: a supply of a multimeric protein complex, comprising multimeric protein and metal aggregating agent; a flow path having a subcutaneous exit, fluidly coupling the multimeric protein supply to the exit; and a porous matrix situated along the flow path comprising: a surface; and a metal chelating agent for the metal aggregating agent; whereby the aggregating agent of the multimeric protein complex contacting the surface is bound to the metal chelating agent to create a monomeric protein flow through the subcutaneous exit.
According to a further embodiment, there is disclosed the device wherein the supply of multimeric protein complex comprises a supply of multimeric insulin.
According to a further embodiment, there is disclosed the device wherein the metal chelating agent is selected from the group consisting of an organic alcohol, a non-acetic acid amine, a phosphine and an organic sulfonate.
According to a further embodiment, there is disclosed the device wherein the metal chelating agent is Nafion .
According to a further embodiment, there is disclosed the device wherein the metal aggregating agent is zinc.
According to a further embodiment, there is disclosed the device wherein the flow path assembly comprises a catheter.
According to a further embodiment, there is disclosed the device wherein the flow path assembly comprises a pump for pumping the multimeric protein complex along the flow path.
According to a further embodiment, there is disclosed the device wherein the pump is adapted to be external to a patient.
According to a further embodiment, there is disclosed the device wherein the pump is adapted to be implantable in a patient to receive the monomeric protein.
2c According to a further embodiment, there is disclosed the device wherein the porous matrix has a porosity of about 4000-20,000 MW.
According to a further embodiment, there is disclosed a kit comprising: (a) the device according to any one of the other embodiments; and (b) instructions to use it to treat a patient.
According to a further embodiment, there is provided a surface carrying a metal chelating agent binding partner for a metal aggregating agent that is associated with a multimeric protein, to generate a monomer of a multimeric protein by binding the metal aggregating agent with the metal chelating agent binding partner carried on the surface and dissociating the multimeric protein into monomers.
According to a further embodiment, a zinc chelating agent bound to a surface for the preparation of monomeric insulin by binding a zinc aggregating agent associated with a multimeric insulin complex with the zinc chelating agent carried on the surface and dissociating multimeric insulin into the monomeric insulin.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a schematic drawing of a device for delivering monomeric protein.
Figs. 2-5 are simplified views of four embodiments of the device of Fig.1.
Fig. 6 is a schematic drawing of a device for delivering monomeric proteins comprising a catheter and a diffusion membrane mounted at one end.
DESCRIPTION OF THE PREFERRED EMBODIMENT
The instant invention provided a general method for dissociating multimeric proteins into monomeric components or subunits by reducing or removing an aggregating agent from a preparation of the multimeric protein. Thus, "aggregating agent" as used herein, refers to a compound, such as a metal ion, required for monomeric subunits of a protein to associate as a multimer. "Aggregating agent" agents which cause the undesirable non-specific association of monomer or multimers of proteins are also included in the scope of the invention. Some examples of aggregating agents include but are not limited to aluminum, calcium, magnesium, zinc, albumin, protamine, antibodies, ligands (including genetic engineered polypeptides, etc.).
Typically, the aggregating agent is removed via a binding partner, such as a chelating agent, antibody, ligand, or receptor. The binding partner typically has an affinity for the aggregating agent of at least twofold, preferably two to tenfold or greater than that of the protein monomer for the aggregating agent. The binding partner is typically immobilized on a carrier surface, such as a matrix or membrane, such that when the protein preparation passed through the matrix the aggregating agent is bound to the binding partner. The surface can be coated with the binding partner or the binding partner inunobilized to the surface or conjugated to the surface or be incorporated as an integral part of the surface by a variety of techniques well known in the art (e. g. , Harlow et al., Antibodies: A Laboratory Manual, pp. 521-538, Cold Spring Harbor Press, Cold Spring Harbor, NY (1988); U.S. 5,505,713; U.S. 5,538,511).
In an embodiment, the surface is a membrane. The membrane typically has pore sizes of a suitable size for monomeric protein to pass through. The pore size is chosen on the basis of the molecular weight of the monomeric protein of interest.
Typically, pore sizes in membranes are described in ranges. Thus, for a given protein of an average molecular weight for a monomer, a preferred range of pore sizes would be 20-50% smaller to 20-50% larger than the average molecular weight of the monomer.
Thus, for example, a preferred pore size for insulin monomers would be about 4000 to about 20,000 MW, more preferably about 4000 to 8000 MW. Typical membranes include cellulose, acetate, polysulfone, TeflonTM or other membranes having a polymeric backbone with holes or pores of a particular size range. In some embodiments, the membrane can be bonded to a cross-section of a catheter by any means known in the art, such as with heat, adhesives, or solvents, or may be mounted on the end of a catheter with a retaining means, such as a retaining ring.
For example, the surface of a polysulfone membrane (W.R. Grace) having a 10,000 MW cutoff, is rendered acidic by soaking the membrane in nitric or sulfuric acid for 30 minutes. Insulin is then passed through the membrane. Insulin at the membrane is destabilized and dissociated into monomers by the chelation of zinc. The monomer easily passes through the membrane, whereas hexamers cannot so diffuse.
Once the surface is coated with zinc ions, it continues to act as an ion-exchange membrane, further destabilizing insulin as long as there are active surface sites available for attraction of zinc ions. This is because the rate of dimerization of insulin is slow compared to the rate of diffusion through the membrane. The preferential passage of monomers through the membrane can be verified by capillary electrophoresis.
In an embodiment, the surface or matrix is a component of a catheter made from a porous material which allows monomeric protein to diffuse out of a predetetmined length of the catheter. Typically, such a device is implanted in a patient.
In some embodiments, the surface or matrix can be a component of a catheter or a fitting on a catheter. The catheter may be external to the patient or may be implanted in the patient. A typical catheter is silicone rubber having an internal dimension of about 0.07 inch and an external dimension of about 0.110 inch. In some embodiments, the protein is pumped through the catheter. The pump can be external to the patient or implanted. Exemplary pumps include but are not limited to MiniMedT"^
Model 507 and MiniMedT"" 2001.
In some embodiments, the matrix, or contacting medium, coated with a binding partner, is used to fill or pack the lumen of a catheter. The protein preparation is passed through the matrix packed catheter, thereby coming in contact with the binding partner.
In some embodiments, insulin is the preferred protein. The aggregating agent in insulin preparations is zinc. The binding partner for zinc ion is typically a chelating agent, such as but not limited to oxygen containing chelators such as organic alcohols and ethers, non-acetic acid amines such as triethylamine and ethylene diamine, phosphorus containing ligands such as phoshines and sulfur based ligands such as organic sulfonates, triethylenetetramine, tetraethylenepentamine, nitriloacetic acid, ethylenediaminetetraacetic acid; N-hydroxyethylenediaminetriacetic acid, ethyletherdiaminetetracetic acid, ethyleneglycol-bis-beta-aminoethylether)N-N
tetracetic acid, diethylene triamine pentaacetic acid, and cyclohexanediamine tetracetic acid. For an implantable pump or catheter system, a preferred chelator would preferably bind the aggregating agent with about a factor of two-fold greater than that of insulin for the 5 aggregating agent. In a preferred embodiment, Nafion (Aldrich, J.
Electrochem. Soc., 140:2279 (1993)) is used as the binding partner on the surface or matrix.
Any commercial insulin preparation can be used in this method for preparing monomeric insulin, including but not limited to HUMULIN RT", VELOSIN
BRT", and HOE21pH U400 and U100 (HoechstT"'). Preferably, the insulin is the commonly termed "regular" insulin. The insulin may be prepared in any buffer or in any aqueous formulation, including sterile water.
In some embodiments, the flow rate through the matrix, contacting medium, or membrane, is typically about 100 l to 2 ml/day.
As an example of the advantages of the invention, the dynamics of insulin absorption in the body can be described as follows. Insulin hexamer is dissociated to insulin dimer, and then to insulin monomer, as described by the following equation 1 (Sluzky et al. Proc Natl. Acad. Sci. 88: 9377-9381 (1991)):
Hexamer Dimer Monomer Ifi k.s k-, 1% ki K-2.89 x 108 K2-1.1 x 103 The local concentration gradient in the patient's tissue drives the equilibrium process according to Le Chatelier's principle. Only monomeric insulin can be absorbed by the capillaries. As the local concentration of monomer decreases by adsorption to the capillaries, the equilibrium shown in Equation 1 shifts to the right as follows in Equation 2:
Dimer Hexamer 312 - 1`22 0- 4 K = 2.89 x 108 =[I6J/[I2]3 Thus, the rate of insulin absorption can be increased in a patient to whom a monomeric insulin has been provided. Similarly, other proteins can be delivered to a patient by the method of the invention to increase rate of absorption, or otherwise enhance therapeutic use of the protein.
An embodiment of the invention is the use of a device having a binding partner specific for an aggregating agent to prepare monomeric protein by contacting the device with a multimeric protein preparation comprising an aggregating agent, thereby binding the aggregating agent to the binding partner and causing dissociation of the multimeric protein onto monomers. The monomers are typically generated during delivery of the protein preparation to the patient.
Other embodiments of the invention include a monomeric protein delivery device 2. The delivery device 2, depicted in Fig. 1, will typically comprise a supply 4 of a multimeric protein, comprising multimeric protein and an aggregating agent; a flow path 6 having a subcutaneous exit 8, fluidly coupling the multimeric protein supply 4 to the exit 8; and a carrier surface assembly 10 situated along the flow path.
The carrier surface assembly 10 comprises a carrier surface, typically a porous matrix 12, and an aggregating agent binding partner carried by the porous matrix. The aggregating agent of the multimeric protein complex passing along the surface is bound to the binding partner on the porous matrix to create a monomeric protein flow 7 through the subcutaneous exit 8. "Subcutaneous" as used herein refers any location below the skin.
In some embodiments the multimeric protein complex preferably comprises a supply of multimeric insulin. The binding partner, can be a chelating agent, as described above, and in some embodiment is preferably Nafion . The aggregating agent, as described above, is preferably zinc in some embodiments.
Fig. 2 illustrates an alternative embodiment of the device 2 of Fig. 1 with like reference numerals referring to like elements. Device 2a comprises a pump 14, such as a microinfusion pump made by MiniMedT"" Inc. of Sylmar, California or HTRON-made by Disetronics of Switzerland. Pump 14 includes the supply of a multimeric protein. Pump 14 is coupled to a catheter 16 having a subcutaneous exit 8a at its distal end, exit 8a being situated beneath skin 18 of the patient.
Fig. 3 illustrates an alternative to the device 2a of Fig. 2. Device 2b replaces porous matrix 12, which is situated along the length of catheter 16 of device 2a, by a porous matrix cap 12b surrounding exit 8b. Either of device 2a or 2b could be implanted beneath skin 18 as suggested by device 2c in Fig. 4. Figure 5 illustrates a further alternative in which the protein preparation and binding partner are provided in separate reservoirs (14d, 22), then mixed in compartment 20 before exiting subcutaneously (8d).
Other types of pumps, such as a manually actuated syringe-type pumps, could also be used, as can pumps which use hydrostatic forces generated across a semipermeable membrane.
EXAMPLE
A device for generating insulin monomers was generated as follows. A
polysulfone dialysis membrane (W.R. Grace) having a MW cut-off of about 10,000 was presoaked in EDTA, then sonically bonded to the end of a silicon rubber (Nusi1T"'). The catheter had an internal dimension of 0.07 inch and an external dimension of 0.110 inch.
catheter with heat. A conunercial preparation of insulin was passed through the membrane and the resulting preparation analyzed by capillary electrophoresis to confum the presence of insulin monomers. The device, depicted in Figure 6, comprises a catheter 22 and a diffusion membrane 24 mounted to one end.
The instant invention provided a general method for dissociating multimeric proteins into monomeric components or subunits by reducing or removing an aggregating agent from a preparation of the multimeric protein. Thus, "aggregating agent" as used herein, refers to a compound, such as a metal ion, required for monomeric subunits of a protein to associate as a multimer. "Aggregating agent" agents which cause the undesirable non-specific association of monomer or multimers of proteins are also included in the scope of the invention. Some examples of aggregating agents include but are not limited to aluminum, calcium, magnesium, zinc, albumin, protamine, antibodies, ligands (including genetic engineered polypeptides, etc.).
Typically, the aggregating agent is removed via a binding partner, such as a chelating agent, antibody, ligand, or receptor. The binding partner typically has an affinity for the aggregating agent of at least twofold, preferably two to tenfold or greater than that of the protein monomer for the aggregating agent. The binding partner is typically immobilized on a carrier surface, such as a matrix or membrane, such that when the protein preparation passed through the matrix the aggregating agent is bound to the binding partner. The surface can be coated with the binding partner or the binding partner inunobilized to the surface or conjugated to the surface or be incorporated as an integral part of the surface by a variety of techniques well known in the art (e. g. , Harlow et al., Antibodies: A Laboratory Manual, pp. 521-538, Cold Spring Harbor Press, Cold Spring Harbor, NY (1988); U.S. 5,505,713; U.S. 5,538,511).
In an embodiment, the surface is a membrane. The membrane typically has pore sizes of a suitable size for monomeric protein to pass through. The pore size is chosen on the basis of the molecular weight of the monomeric protein of interest.
Typically, pore sizes in membranes are described in ranges. Thus, for a given protein of an average molecular weight for a monomer, a preferred range of pore sizes would be 20-50% smaller to 20-50% larger than the average molecular weight of the monomer.
Thus, for example, a preferred pore size for insulin monomers would be about 4000 to about 20,000 MW, more preferably about 4000 to 8000 MW. Typical membranes include cellulose, acetate, polysulfone, TeflonTM or other membranes having a polymeric backbone with holes or pores of a particular size range. In some embodiments, the membrane can be bonded to a cross-section of a catheter by any means known in the art, such as with heat, adhesives, or solvents, or may be mounted on the end of a catheter with a retaining means, such as a retaining ring.
For example, the surface of a polysulfone membrane (W.R. Grace) having a 10,000 MW cutoff, is rendered acidic by soaking the membrane in nitric or sulfuric acid for 30 minutes. Insulin is then passed through the membrane. Insulin at the membrane is destabilized and dissociated into monomers by the chelation of zinc. The monomer easily passes through the membrane, whereas hexamers cannot so diffuse.
Once the surface is coated with zinc ions, it continues to act as an ion-exchange membrane, further destabilizing insulin as long as there are active surface sites available for attraction of zinc ions. This is because the rate of dimerization of insulin is slow compared to the rate of diffusion through the membrane. The preferential passage of monomers through the membrane can be verified by capillary electrophoresis.
In an embodiment, the surface or matrix is a component of a catheter made from a porous material which allows monomeric protein to diffuse out of a predetetmined length of the catheter. Typically, such a device is implanted in a patient.
In some embodiments, the surface or matrix can be a component of a catheter or a fitting on a catheter. The catheter may be external to the patient or may be implanted in the patient. A typical catheter is silicone rubber having an internal dimension of about 0.07 inch and an external dimension of about 0.110 inch. In some embodiments, the protein is pumped through the catheter. The pump can be external to the patient or implanted. Exemplary pumps include but are not limited to MiniMedT"^
Model 507 and MiniMedT"" 2001.
In some embodiments, the matrix, or contacting medium, coated with a binding partner, is used to fill or pack the lumen of a catheter. The protein preparation is passed through the matrix packed catheter, thereby coming in contact with the binding partner.
In some embodiments, insulin is the preferred protein. The aggregating agent in insulin preparations is zinc. The binding partner for zinc ion is typically a chelating agent, such as but not limited to oxygen containing chelators such as organic alcohols and ethers, non-acetic acid amines such as triethylamine and ethylene diamine, phosphorus containing ligands such as phoshines and sulfur based ligands such as organic sulfonates, triethylenetetramine, tetraethylenepentamine, nitriloacetic acid, ethylenediaminetetraacetic acid; N-hydroxyethylenediaminetriacetic acid, ethyletherdiaminetetracetic acid, ethyleneglycol-bis-beta-aminoethylether)N-N
tetracetic acid, diethylene triamine pentaacetic acid, and cyclohexanediamine tetracetic acid. For an implantable pump or catheter system, a preferred chelator would preferably bind the aggregating agent with about a factor of two-fold greater than that of insulin for the 5 aggregating agent. In a preferred embodiment, Nafion (Aldrich, J.
Electrochem. Soc., 140:2279 (1993)) is used as the binding partner on the surface or matrix.
Any commercial insulin preparation can be used in this method for preparing monomeric insulin, including but not limited to HUMULIN RT", VELOSIN
BRT", and HOE21pH U400 and U100 (HoechstT"'). Preferably, the insulin is the commonly termed "regular" insulin. The insulin may be prepared in any buffer or in any aqueous formulation, including sterile water.
In some embodiments, the flow rate through the matrix, contacting medium, or membrane, is typically about 100 l to 2 ml/day.
As an example of the advantages of the invention, the dynamics of insulin absorption in the body can be described as follows. Insulin hexamer is dissociated to insulin dimer, and then to insulin monomer, as described by the following equation 1 (Sluzky et al. Proc Natl. Acad. Sci. 88: 9377-9381 (1991)):
Hexamer Dimer Monomer Ifi k.s k-, 1% ki K-2.89 x 108 K2-1.1 x 103 The local concentration gradient in the patient's tissue drives the equilibrium process according to Le Chatelier's principle. Only monomeric insulin can be absorbed by the capillaries. As the local concentration of monomer decreases by adsorption to the capillaries, the equilibrium shown in Equation 1 shifts to the right as follows in Equation 2:
Dimer Hexamer 312 - 1`22 0- 4 K = 2.89 x 108 =[I6J/[I2]3 Thus, the rate of insulin absorption can be increased in a patient to whom a monomeric insulin has been provided. Similarly, other proteins can be delivered to a patient by the method of the invention to increase rate of absorption, or otherwise enhance therapeutic use of the protein.
An embodiment of the invention is the use of a device having a binding partner specific for an aggregating agent to prepare monomeric protein by contacting the device with a multimeric protein preparation comprising an aggregating agent, thereby binding the aggregating agent to the binding partner and causing dissociation of the multimeric protein onto monomers. The monomers are typically generated during delivery of the protein preparation to the patient.
Other embodiments of the invention include a monomeric protein delivery device 2. The delivery device 2, depicted in Fig. 1, will typically comprise a supply 4 of a multimeric protein, comprising multimeric protein and an aggregating agent; a flow path 6 having a subcutaneous exit 8, fluidly coupling the multimeric protein supply 4 to the exit 8; and a carrier surface assembly 10 situated along the flow path.
The carrier surface assembly 10 comprises a carrier surface, typically a porous matrix 12, and an aggregating agent binding partner carried by the porous matrix. The aggregating agent of the multimeric protein complex passing along the surface is bound to the binding partner on the porous matrix to create a monomeric protein flow 7 through the subcutaneous exit 8. "Subcutaneous" as used herein refers any location below the skin.
In some embodiments the multimeric protein complex preferably comprises a supply of multimeric insulin. The binding partner, can be a chelating agent, as described above, and in some embodiment is preferably Nafion . The aggregating agent, as described above, is preferably zinc in some embodiments.
Fig. 2 illustrates an alternative embodiment of the device 2 of Fig. 1 with like reference numerals referring to like elements. Device 2a comprises a pump 14, such as a microinfusion pump made by MiniMedT"" Inc. of Sylmar, California or HTRON-made by Disetronics of Switzerland. Pump 14 includes the supply of a multimeric protein. Pump 14 is coupled to a catheter 16 having a subcutaneous exit 8a at its distal end, exit 8a being situated beneath skin 18 of the patient.
Fig. 3 illustrates an alternative to the device 2a of Fig. 2. Device 2b replaces porous matrix 12, which is situated along the length of catheter 16 of device 2a, by a porous matrix cap 12b surrounding exit 8b. Either of device 2a or 2b could be implanted beneath skin 18 as suggested by device 2c in Fig. 4. Figure 5 illustrates a further alternative in which the protein preparation and binding partner are provided in separate reservoirs (14d, 22), then mixed in compartment 20 before exiting subcutaneously (8d).
Other types of pumps, such as a manually actuated syringe-type pumps, could also be used, as can pumps which use hydrostatic forces generated across a semipermeable membrane.
EXAMPLE
A device for generating insulin monomers was generated as follows. A
polysulfone dialysis membrane (W.R. Grace) having a MW cut-off of about 10,000 was presoaked in EDTA, then sonically bonded to the end of a silicon rubber (Nusi1T"'). The catheter had an internal dimension of 0.07 inch and an external dimension of 0.110 inch.
catheter with heat. A conunercial preparation of insulin was passed through the membrane and the resulting preparation analyzed by capillary electrophoresis to confum the presence of insulin monomers. The device, depicted in Figure 6, comprises a catheter 22 and a diffusion membrane 24 mounted to one end.
Claims (28)
1. The use of a surface carrying a metal chelating agent binding partner for a metal aggregating agent that is associated with a multimeric protein, to generate a monomer of a multimeric protein by binding the metal aggregating agent with the metal chelating agent binding partner carried on the surface and dissociating the multimeric protein into monomers.
2. The use according to claim 1 wherein the metal aggregating agent is in a preparation of a multimeric protein.
3. The use according to claim 1 or 2, wherein the monomeric protein is insulin.
4. The use according to claim 1 or 2, wherein the metal aggregating agent is zinc.
5. The use according to claim 1 wherein the metal chelating agent binding partner is an ion exchange medium.
6. The use according to claim 1 or 2, wherein the surface is a membrane.
7. The use according to claim 6, wherein the membrane comprises pores of about 4000 to about 20,000MW.
8. The use according to claim 1 or 2, wherein the multimeric protein is pumped through the surface.
9. The use according to any one of claims 1 to 8, wherein the surface is adapted to be implantable.
10. A method for dissociating a multimeric insulin, the method comprising:
(a) binding a zinc chelating agent to a surface;
(b) contacting the surface with the multimeric insulin, whereby zinc associated with the multimeric insulin complex binds to the zinc chelating agent and the multimeric insulin is dissociated into monomers; and (c) recovering monomeric insulin generated by step (b).
(a) binding a zinc chelating agent to a surface;
(b) contacting the surface with the multimeric insulin, whereby zinc associated with the multimeric insulin complex binds to the zinc chelating agent and the multimeric insulin is dissociated into monomers; and (c) recovering monomeric insulin generated by step (b).
11. The use of a preparation made by the method of claim 10, wherein the monomeric insulin is suitable for administration to a patient.
12. The use according to claim 11 further comprising pumping said monomeric insulin.
13. The method of any one of claims 10 to 12, wherein the surface is adapted to be implantable.
14. The use of a zinc chelating agent bound to a surface to treat a patient with monomeric insulin by binding a zinc aggregating agent associated with a multimeric insulin complex with the zinc chelating agent carried on the surface and dissociating multimeric insulin into the monomeric insulin.
15. The use according to claim 14 comprising contacting the multimeric insulin with the surface on an insulin delivery device and dissociating the multimeric insulin into monomers.
16. A monomeric protein delivery device comprising:
a supply of a multimeric protein complex, comprising multimeric protein and an metal aggregating agent;
a flow path having a subcutaneous exit, fluidly coupling the multimeric protein supply to the exit; and a porous matrix situated along the flow path comprising:
a surface; and a metal chelating agent for the metal aggregating agent;
whereby the metal aggregating agent of the multimeric protein complex contacting the surface is bound to the metal chelating agent to create a monomeric protein flow through the subcutaneous exit.
a supply of a multimeric protein complex, comprising multimeric protein and an metal aggregating agent;
a flow path having a subcutaneous exit, fluidly coupling the multimeric protein supply to the exit; and a porous matrix situated along the flow path comprising:
a surface; and a metal chelating agent for the metal aggregating agent;
whereby the metal aggregating agent of the multimeric protein complex contacting the surface is bound to the metal chelating agent to create a monomeric protein flow through the subcutaneous exit.
17. The device according to claim 16, wherein the supply of multimeric protein complex comprises a supply of multimeric insulin.
18. The device according to claims 16 and 17, wherein the metal chelating agent is selected from the group consisting of an organic alcohol, a non-acetic acid amine, a phosphine and an organic sulfonate.
19. The device according to any one of claims 16 to 18, wherein the metal chelating agent is Nafion®.
20. The device according to any one of claims 16 to 19, wherein the metal aggregating agent is zinc.
21. The device according to any one of claims 16 to 20, wherein the flow path assembly comprises a catheter.
22. The device according to any one of claims 16 to 21, wherein the flow path assembly comprises a pump for pumping the multimeric protein complex along the flow path.
23. The device according to claim 22, wherein the pump is adapted to be external to a patient.
24. The device according to claim 22, wherein the pump is adapted to be implantable in a patient to receive the monomeric protein.
25. The device according to claim 16, wherein the porous matrix has a porosity of about 4000-20,000 MW.
26. A kit comprising:
(a) the device according to any one of claims 16 to 25; and (b) instructions to use it to treat a patient.
(a) the device according to any one of claims 16 to 25; and (b) instructions to use it to treat a patient.
27. The use of a zinc chelating agent bound to a surface for the preparation of monomeric insulin by binding a zinc aggregating agent associated with a multimeric insulin complex with the zinc chelating agent carried on the surface and dissociating multimeric insulin into the monomeric insulin.
28. The use according to claim 27 comprising contacting the multimeric insulin with the surface on an insulin delivery device and dissociating the multimeric insulin into monomers.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US661195P | 1995-11-13 | 1995-11-13 | |
| US60/006,611 | 1995-11-13 | ||
| PCT/US1996/018115 WO1997017945A2 (en) | 1995-11-13 | 1996-11-12 | Methods and compositions for the delivery of monomeric proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2236579A1 CA2236579A1 (en) | 1997-05-22 |
| CA2236579C true CA2236579C (en) | 2009-06-30 |
Family
ID=21721720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002236579A Expired - Fee Related CA2236579C (en) | 1995-11-13 | 1996-11-12 | Methods and compositions for the delivery of monomeric proteins |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5807315A (en) |
| EP (1) | EP0861089B1 (en) |
| JP (1) | JP4307550B2 (en) |
| AU (1) | AU7678196A (en) |
| CA (1) | CA2236579C (en) |
| DE (1) | DE69622421T2 (en) |
| DK (1) | DK0861089T3 (en) |
| WO (1) | WO1997017945A2 (en) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6428771B1 (en) * | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
| US6042561A (en) * | 1997-10-22 | 2000-03-28 | Ash Medical Systems, Inc. | Non-intravascular infusion access device |
| US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
| US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
| US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US9006175B2 (en) * | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| PT1808438E (en) * | 1999-06-29 | 2015-01-14 | Mannkind Corp | Purification and stabilization of peptide and proteins in pharmaceutical agents |
| US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
| US7041468B2 (en) | 2001-04-02 | 2006-05-09 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
| WO2003080149A2 (en) | 2002-03-20 | 2003-10-02 | Mannkind Corporation | Inhalation apparatus |
| US7811231B2 (en) | 2002-12-31 | 2010-10-12 | Abbott Diabetes Care Inc. | Continuous glucose monitoring system and methods of use |
| JP4565193B2 (en) | 2003-04-23 | 2010-10-20 | バレリタス， インコーポレイテッド | Hydraulically operated pump for long duration pharmaceutical administration |
| US8066639B2 (en) | 2003-06-10 | 2011-11-29 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
| US7338171B2 (en) * | 2003-10-27 | 2008-03-04 | Jen-Chuen Hsieh | Method and apparatus for visual drive control |
| EP1708738B1 (en) * | 2004-01-12 | 2016-05-04 | MannKind Corporation | A method of reducing serum proinsulin levels in type 2 diabetics |
| WO2005089103A2 (en) | 2004-02-17 | 2005-09-29 | Therasense, Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
| US20080090753A1 (en) | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
| US20080248999A1 (en) * | 2007-04-04 | 2008-10-09 | Biodel Inc. | Amylin formulations |
| US20080085298A1 (en) * | 2004-03-12 | 2008-04-10 | Biodel, Inc. | Rapid Mucosal Gel or Film Insulin Compositions |
| PT2319500E (en) * | 2004-03-12 | 2013-01-23 | Biodel Inc | Rapid acting drug delivery compositions |
| US20080096800A1 (en) * | 2004-03-12 | 2008-04-24 | Biodel, Inc. | Rapid mucosal gel or film insulin compositions |
| US9089636B2 (en) | 2004-07-02 | 2015-07-28 | Valeritas, Inc. | Methods and devices for delivering GLP-1 and uses thereof |
| JP5078014B2 (en) | 2004-08-20 | 2012-11-21 | マンカインド コーポレイション | Catalytic reaction of diketopiperazine synthesis. |
| HUE026797T2 (en) | 2004-08-23 | 2016-07-28 | Mannkind Corp | Diketopiperazine salts for drug delivery |
| DE102005011656A1 (en) * | 2005-03-14 | 2006-09-21 | Breeze Medical, Inc., Boca Raton | System for delivering an agent into a blood vessel |
| US8112240B2 (en) | 2005-04-29 | 2012-02-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing leak detection in data monitoring and management systems |
| KR20120060245A (en) | 2005-09-14 | 2012-06-11 | 맨카인드 코포레이션 | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
| US7713929B2 (en) | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| US20070086952A1 (en) * | 2005-09-29 | 2007-04-19 | Biodel, Inc. | Rapid Acting and Prolonged Acting Inhalable Insulin Preparations |
| US8084420B2 (en) * | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| US7766829B2 (en) | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
| EP2497484A3 (en) | 2006-02-22 | 2012-11-07 | MannKind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
| EP2005309B1 (en) | 2006-03-30 | 2016-02-17 | Valeritas, Inc. | Multi-cartridge fluid delivery device |
| US7620438B2 (en) | 2006-03-31 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
| US8226891B2 (en) | 2006-03-31 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
| US7718609B2 (en) * | 2006-04-12 | 2010-05-18 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| US7920907B2 (en) | 2006-06-07 | 2011-04-05 | Abbott Diabetes Care Inc. | Analyte monitoring system and method |
| US10154804B2 (en) | 2007-01-31 | 2018-12-18 | Medtronic Minimed, Inc. | Model predictive method and system for controlling and supervising insulin infusion |
| US8732188B2 (en) | 2007-02-18 | 2014-05-20 | Abbott Diabetes Care Inc. | Method and system for providing contextual based medication dosage determination |
| US8930203B2 (en) | 2007-02-18 | 2015-01-06 | Abbott Diabetes Care Inc. | Multi-function analyte test device and methods therefor |
| US8123686B2 (en) | 2007-03-01 | 2012-02-28 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
| US8665091B2 (en) | 2007-05-08 | 2014-03-04 | Abbott Diabetes Care Inc. | Method and device for determining elapsed sensor life |
| US7928850B2 (en) | 2007-05-08 | 2011-04-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
| US8461985B2 (en) | 2007-05-08 | 2013-06-11 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
| US8456301B2 (en) | 2007-05-08 | 2013-06-04 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
| MX2010007342A (en) * | 2008-01-04 | 2010-08-26 | Biodel Inc | Insulin formulations for insulin release as a function of tissue glucose levels. |
| US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
| EP3281663B8 (en) | 2008-06-13 | 2022-09-21 | MannKind Corporation | Breath powered dry powder inhaler for drug delivery |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| US9364619B2 (en) | 2008-06-20 | 2016-06-14 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
| TWI494123B (en) | 2008-08-11 | 2015-08-01 | Mannkind Corp | Use of ultrarapid acting insulin |
| US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
| US8650937B2 (en) | 2008-09-19 | 2014-02-18 | Tandem Diabetes Care, Inc. | Solute concentration measurement device and related methods |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| US8103456B2 (en) | 2009-01-29 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
| US9060927B2 (en) * | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
| CA2754595C (en) | 2009-03-11 | 2017-06-27 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
| WO2010127050A1 (en) | 2009-04-28 | 2010-11-04 | Abbott Diabetes Care Inc. | Error detection in critical repeating data in a wireless sensor system |
| WO2010138856A1 (en) | 2009-05-29 | 2010-12-02 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
| WO2010144789A2 (en) | 2009-06-12 | 2010-12-16 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
| CA2769030C (en) | 2009-07-30 | 2016-05-10 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
| US8993331B2 (en) | 2009-08-31 | 2015-03-31 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods for managing power and noise |
| US9314195B2 (en) | 2009-08-31 | 2016-04-19 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
| US9320461B2 (en) | 2009-09-29 | 2016-04-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
| CA2778698A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
| AU2011271097B2 (en) | 2010-06-21 | 2014-11-27 | Mannkind Corporation | Dry powder drug delivery system and methods |
| CN105667994B (en) | 2011-04-01 | 2018-04-06 | 曼金德公司 | Blister package for pharmaceutical kit |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| KR20140095483A (en) | 2011-10-24 | 2014-08-01 | 맨카인드 코포레이션 | Methods and compositions for treating pain |
| AU2012335830B2 (en) | 2011-11-07 | 2017-05-04 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods |
| US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
| DK2872205T3 (en) | 2012-07-12 | 2017-02-27 | Mannkind Corp | DRY POWDER FORMAL ADMINISTRATION SYSTEM |
| US9878096B2 (en) | 2012-08-30 | 2018-01-30 | Medtronic Minimed, Inc. | Generation of target glucose values for a closed-loop operating mode of an insulin infusion system |
| US20140066884A1 (en) | 2012-08-30 | 2014-03-06 | Medtronic Minimed, Inc. | Sensor model supervisor for a closed-loop insulin infusion system |
| US9849239B2 (en) | 2012-08-30 | 2017-12-26 | Medtronic Minimed, Inc. | Generation and application of an insulin limit for a closed-loop operating mode of an insulin infusion system |
| US9662445B2 (en) | 2012-08-30 | 2017-05-30 | Medtronic Minimed, Inc. | Regulating entry into a closed-loop operating mode of an insulin infusion system |
| CN104769595B (en) | 2012-08-30 | 2017-12-08 | 美敦力迷你迈德公司 | Guard technology for closed-loop insulin infusion system |
| US10496797B2 (en) | 2012-08-30 | 2019-12-03 | Medtronic Minimed, Inc. | Blood glucose validation for a closed-loop operating mode of an insulin infusion system |
| US9623179B2 (en) | 2012-08-30 | 2017-04-18 | Medtronic Minimed, Inc. | Safeguarding techniques for a closed-loop insulin infusion system |
| US10130767B2 (en) | 2012-08-30 | 2018-11-20 | Medtronic Minimed, Inc. | Sensor model supervisor for a closed-loop insulin infusion system |
| US9968306B2 (en) | 2012-09-17 | 2018-05-15 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
| WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
| JP6322642B2 (en) | 2012-11-13 | 2018-05-09 | アドシア | Fast-acting insulin preparation containing a substituted anionic compound |
| US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
| KR102499439B1 (en) | 2013-03-15 | 2023-02-13 | 맨카인드 코포레이션 | Microcrystalline diketopiperazine compositions and methods |
| WO2015010092A1 (en) | 2013-07-18 | 2015-01-22 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
| JP2016530930A (en) | 2013-08-05 | 2016-10-06 | マンカインド コーポレイション | Ventilation device and method |
| WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| GB201607918D0 (en) | 2016-05-06 | 2016-06-22 | Arecor Ltd | Novel formulations |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US507885A (en) * | 1893-10-31 | Apparatus for purifying asphalt | ||
| US4183849A (en) * | 1975-01-15 | 1980-01-15 | Nordisk Insulinlaboratorium | Therapeutic insulin preparation and a process for the production of a stable insulin preparation with protracted effect |
| FI78616C (en) * | 1982-02-05 | 1989-09-11 | Novo Industri As | Process for preparing an infused stabilized insulin solution having an elevated zinc content |
| US4459226A (en) * | 1982-02-26 | 1984-07-10 | Eli Lilly And Company | Process for recovering insulin |
| US4861705A (en) * | 1983-01-31 | 1989-08-29 | Yeda Research And Development Company, Ltd. | Method for removing components of biological fluids |
| US4940456A (en) * | 1987-02-10 | 1990-07-10 | Dan Sibalis | Electrolytic transdermal delivery of proteins |
| US4931498A (en) * | 1988-02-25 | 1990-06-05 | Purdue Research Foundation | Immobilized artificial membranes |
| US5597485A (en) * | 1988-05-13 | 1997-01-28 | Vilmax S.A. | Process for separating proteins |
| US5130298A (en) * | 1989-05-16 | 1992-07-14 | Ethicon, Inc. | Stabilized compositions containing epidermal growth factor |
| DK10191D0 (en) * | 1991-01-22 | 1991-01-22 | Novo Nordisk As | HIS UNKNOWN PEPTIDES |
| US5505713A (en) * | 1994-04-01 | 1996-04-09 | Minimed Inc. | Indwelling catheter with stable enzyme coating |
| JP3148591B2 (en) * | 1994-09-13 | 2001-03-19 | トヨタ自動車株式会社 | Method and apparatus for separating / removing metal contained in solution |
-
1996
- 1996-11-12 US US08/747,923 patent/US5807315A/en not_active Expired - Lifetime
- 1996-11-12 WO PCT/US1996/018115 patent/WO1997017945A2/en active IP Right Grant
- 1996-11-12 EP EP96939664A patent/EP0861089B1/en not_active Expired - Lifetime
- 1996-11-12 JP JP51899697A patent/JP4307550B2/en not_active Expired - Fee Related
- 1996-11-12 CA CA002236579A patent/CA2236579C/en not_active Expired - Fee Related
- 1996-11-12 AU AU76781/96A patent/AU7678196A/en not_active Abandoned
- 1996-11-12 DK DK96939664T patent/DK0861089T3/en active
- 1996-11-12 DE DE69622421T patent/DE69622421T2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69622421T2 (en) | 2003-03-20 |
| DK0861089T3 (en) | 2002-10-07 |
| WO1997017945A3 (en) | 1997-07-10 |
| US5807315A (en) | 1998-09-15 |
| WO1997017945A2 (en) | 1997-05-22 |
| JP4307550B2 (en) | 2009-08-05 |
| JP2000502993A (en) | 2000-03-14 |
| EP0861089B1 (en) | 2002-07-17 |
| AU7678196A (en) | 1997-06-05 |
| CA2236579A1 (en) | 1997-05-22 |
| EP0861089A2 (en) | 1998-09-02 |
| DE69622421D1 (en) | 2002-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2236579C (en) | Methods and compositions for the delivery of monomeric proteins | |
| FI78616C (en) | Process for preparing an infused stabilized insulin solution having an elevated zinc content | |
| US4529719A (en) | Modified crosslinked stroma-free tetrameric hemoglobin | |
| AU2006314251B2 (en) | Pharmaceutical device for the administration of substances to patients | |
| EP0882448A1 (en) | Method of encapsulating biologically active agents within erythrocytes and apparatus therefor | |
| US9994615B2 (en) | Self-regulated peptide hydrogel for insulin delivery | |
| JP2009502930A (en) | Removal of peroxide from drug delivery vehicles | |
| JP4961343B2 (en) | Long-acting colloidal insulin preparation and its preparation | |
| WO2003064462A1 (en) | Peg-binding pth or peg-binding pth derivative | |
| Ton et al. | Albumin‐Coated Amberlite XAD‐7 Resin for Hemoperfusion in Acute Liver Failure: Part I: Adsorption Studies | |
| EP0399781B1 (en) | Stabilized calcitonin pharmaceutical composition | |
| CN109731169A (en) | For reducing the new compositions and preparation method thereof of beta-amyloid protein in vitro | |
| Swi Chang | Red blood cell substitutes: microencapsulated hemoglobin and cross-linked hemoglobin including pyridoxylated polyhemoglobin & conjugated hemoglobin | |
| CN101200499A (en) | Method for preparing narrow-distribution low average molecular weight polymerized hemoglobin | |
| EP0914147A1 (en) | Atrial natriuretic peptide (anp) as an additive to peritoneal dialysis solutions | |
| EP1423157A2 (en) | Stabilizing catheter for protein drug delivery | |
| US7285379B2 (en) | Artificial oxygen carrier and production method thereof | |
| JPH04502768A (en) | Stabilization and sustained release vehicle for hydrophobic protein aqueous solutions | |
| EP0285286A1 (en) | Method for stabilising proteins | |
| SK68799A3 (en) | Topical preparation for introducing peptidaceous pharmacons in living organisms | |
| Kost et al. | Smart polymers for controlled drug delivery | |
| Margel | Agarose-polymeric microsphere beads: specific new adsorbents for hemoperfusion | |
| AU2022291929A1 (en) | Modified tnf as a capture ligand | |
| KR100197739B1 (en) | Chemical-modification method of red blood cell by glutaraldehydro | |
| Schmer | Enzyme Reactors Consisting of Matrix‐Bound or Entrapped Red Cell Ghosts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20151112 |